Targeted therapy in oncology: The agony and ectasy of personalized medicine

Expert Review of Anticancer Therapy

Volumn 1, Issue 3, 2001, Pages 321-322

  Ross, Jeffrey S ^a   Greene, Barry ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; IMATINIB; TRASTUZUMAB;

BREAST CANCER; CHRONIC MYELOID LEUKEMIA; DIAGNOSTIC PROCEDURE; DRUG COST; DRUG MARKETING; DRUG SYNTHESIS; DRUG TARGETING; EDITORIAL; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; INDIVIDUALIZATION; ONCOGENE NEU; ONCOLOGY; PHARMACOGENOMICS; SIDE EFFECT;

EID: 0035557926     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.1.3.321     Document Type: Editorial

References (11)

1. Chronic myelogenous leukaemia-new therapeutic principles
2. ST1571: Targeting BCR-ABL as therapy for CML
3. New hope for cancer
4. In search of the silver bullet
5. Steroid hormone receptors in breast cancer management
6. The Her-2/neu oncogene: Prognostic factor, predictive factor and target for therapy
7. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
8. The EGF receptor family as targets for cancer therapy
9. Transcriptional profiling in cancer: The path to clinical pharmacogenomics
10. Cluster analysis and promoter modelling as bioinformatics tools for the identification of target genes from expression array data
11. Applications of proteomics in oncology